Go Pro
→ 60 years. Zero competitors. (From Behind the Markets) (Ad)tc pixel Free NMTC Stock Alerts

NeuroOne Medical Technologies (NMTC) Competitors

NeuroOne Medical Technologies logo
$2.16 -0.18 (-7.69%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 +0.01 (+0.46%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NMTC vs. NRXS, OM, SPAI, NNOX, and LNSR

Should you buy NeuroOne Medical Technologies stock or one of its competitors? MarketBeat compares NeuroOne Medical Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroOne Medical Technologies include NeurAxis (NRXS), Outset Medical (OM), Safe Pro Group (SPAI), Nano-X Imaging (NNOX), and LENSAR (LNSR). These companies are all part of the "medical equipment" industry.

How does NeuroOne Medical Technologies compare to NeurAxis?

NeurAxis (NASDAQ:NRXS) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than NeurAxis. MarketBeat recorded 1 mentions for NeuroOne Medical Technologies and 0 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.00 beat NeuroOne Medical Technologies' score of -1.22 indicating that NeurAxis is being referred to more favorably in the media.

Company Overall Sentiment
NeurAxis Neutral
NeuroOne Medical Technologies Negative

NeurAxis currently has a consensus price target of $13.00, indicating a potential upside of 89.50%. NeuroOne Medical Technologies has a consensus price target of $11.67, indicating a potential upside of 440.12%. Given NeuroOne Medical Technologies' higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than NeurAxis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

NeuroOne Medical Technologies has a net margin of -68.35% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
NeurAxis-492.76% N/A -641.25%
NeuroOne Medical Technologies -68.35%-99.43%-70.40%

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeurAxis has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

NeuroOne Medical Technologies has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeurAxis$4.28M19.84-$14.63M-$0.81N/A
NeuroOne Medical Technologies$12.10M1.55-$3.61M-$0.85N/A

Summary

NeuroOne Medical Technologies beats NeurAxis on 9 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Outset Medical?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

NeuroOne Medical Technologies has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Outset Medical has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

NeuroOne Medical Technologies presently has a consensus target price of $11.67, suggesting a potential upside of 440.12%. Outset Medical has a consensus target price of $10.00, suggesting a potential upside of 146.31%. Given NeuroOne Medical Technologies' higher probable upside, equities research analysts plainly believe NeuroOne Medical Technologies is more favorable than Outset Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Outset Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 2.5% of Outset Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Outset Medical had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Outset Medical and 1 mentions for NeuroOne Medical Technologies. Outset Medical's average media sentiment score of 0.93 beat NeuroOne Medical Technologies' score of -1.22 indicating that Outset Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroOne Medical Technologies
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
Outset Medical
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NeuroOne Medical Technologies has higher earnings, but lower revenue than Outset Medical. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$12.10M1.55-$3.61M-$0.85N/A
Outset Medical$119.48M0.63-$81.65M-$4.16N/A

Outset Medical has a net margin of -63.65% compared to NeuroOne Medical Technologies' net margin of -68.35%. Outset Medical's return on equity of -56.13% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-68.35% -99.43% -70.40%
Outset Medical -63.65%-56.13%-27.45%

Summary

Outset Medical beats NeuroOne Medical Technologies on 8 of the 14 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Safe Pro Group?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Safe Pro Group (NASDAQ:SPAI) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Safe Pro Group had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 2 mentions for Safe Pro Group and 1 mentions for NeuroOne Medical Technologies. Safe Pro Group's average media sentiment score of 0.65 beat NeuroOne Medical Technologies' score of -1.22 indicating that Safe Pro Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroOne Medical Technologies
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
Safe Pro Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NeuroOne Medical Technologies has a net margin of -68.35% compared to Safe Pro Group's net margin of -800.91%. NeuroOne Medical Technologies' return on equity of -99.43% beat Safe Pro Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-68.35% -99.43% -70.40%
Safe Pro Group -800.91%-119.17%-107.17%

NeuroOne Medical Technologies currently has a consensus target price of $11.67, indicating a potential upside of 440.12%. Safe Pro Group has a consensus target price of $11.00, indicating a potential upside of 194.12%. Given NeuroOne Medical Technologies' higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Safe Pro Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Safe Pro Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

NeuroOne Medical Technologies has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Safe Pro Group has a beta of 3.52, suggesting that its stock price is 252% more volatile than the broader market.

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 54.8% of Safe Pro Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NeuroOne Medical Technologies has higher revenue and earnings than Safe Pro Group. Safe Pro Group is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$12.10M1.55-$3.61M-$0.85N/A
Safe Pro Group$610K128.08-$14.32M-$0.71N/A

Summary

NeuroOne Medical Technologies beats Safe Pro Group on 9 of the 17 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Nano-X Imaging?

Nano-X Imaging (NASDAQ:NNOX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

NeuroOne Medical Technologies has lower revenue, but higher earnings than Nano-X Imaging. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nano-X Imaging$13.02M5.93-$75.02M-$1.58N/A
NeuroOne Medical Technologies$12.10M1.55-$3.61M-$0.85N/A

21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NeuroOne Medical Technologies has a net margin of -68.35% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Nano-X Imaging-716.44% -70.96% -62.26%
NeuroOne Medical Technologies -68.35%-99.43%-70.40%

Nano-X Imaging currently has a consensus price target of $4.00, indicating a potential upside of 260.36%. NeuroOne Medical Technologies has a consensus price target of $11.67, indicating a potential upside of 440.12%. Given NeuroOne Medical Technologies' higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Nano-X Imaging.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nano-X Imaging
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Nano-X Imaging has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, Nano-X Imaging had 17 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 18 mentions for Nano-X Imaging and 1 mentions for NeuroOne Medical Technologies. Nano-X Imaging's average media sentiment score of 0.00 beat NeuroOne Medical Technologies' score of -1.22 indicating that Nano-X Imaging is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nano-X Imaging
0 Very Positive mention(s)
0 Positive mention(s)
18 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NeuroOne Medical Technologies
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

Summary

Nano-X Imaging beats NeuroOne Medical Technologies on 11 of the 17 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to LENSAR?

LENSAR (NASDAQ:LNSR) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LENSAR has a net margin of 50.94% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -99.43% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
LENSAR50.94% -183.19% 42.26%
NeuroOne Medical Technologies -68.35%-99.43%-70.40%

LENSAR presently has a consensus target price of $10.00, indicating a potential upside of 73.91%. NeuroOne Medical Technologies has a consensus target price of $11.67, indicating a potential upside of 440.12%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENSAR
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

NeuroOne Medical Technologies has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENSAR$58.44M1.21-$34.28M-$0.58N/A
NeuroOne Medical Technologies$12.10M1.55-$3.61M-$0.85N/A

LENSAR has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, LENSAR and LENSAR both had 1 articles in the media. LENSAR's average media sentiment score of 1.90 beat NeuroOne Medical Technologies' score of -1.22 indicating that LENSAR is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENSAR
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
NeuroOne Medical Technologies
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

Summary

LENSAR beats NeuroOne Medical Technologies on 8 of the 15 factors compared between the two stocks.

Get NeuroOne Medical Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTC vs. The Competition

Export
MetricNeuroOne Medical TechnologiesMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$20.36M$9.65B$6.90B$12.28B
Dividend YieldN/A1.60%2.67%9.39%
P/E Ratio-2.5426.6227.1023.94
Price / Sales1.5518.93517.5191.92
Price / CashN/A15.0326.6847.25
Price / Book2.546.1410.666.14
Net Income-$3.61M$179.69M$3.60B$331.74M
7 Day Performance-18.80%-0.73%-1.51%-1.72%
1 Month Performance-34.35%4.88%1.11%-1.44%
1 Year Performance-57.65%14.56%23.77%16.97%

NeuroOne Medical Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTC
NeuroOne Medical Technologies
2.4467 of 5 stars		$2.16
-7.7%		$11.67
+440.1%		-54.1%$20.36M$12.10MN/A20
NRXS
NeurAxis
1.3958 of 5 stars		$7.15
+3.9%		$13.00
+81.8%		+157.6%$88.55M$4.28MN/A19
OM
Outset Medical
3.74 of 5 stars		$4.54
+4.1%		$10.00
+120.3%		-75.9%$80.82M$119.48MN/A520
SPAI
Safe Pro Group
2.4269 of 5 stars		$3.84
+4.1%		$10.00
+160.4%		-2.8%$77.06M$610KN/A11
NNOX
Nano-X Imaging
3.0618 of 5 stars		$1.06
+1.0%		$4.00
+277.4%		-78.2%$73.07M$13.02MN/A190

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTC) was last updated on 7/20/2026 by MarketBeat.com Staff.
From Our Partners
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
NVIDIA offered $40B. The answer was no.
Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...
Behind the Markets | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump is positioned. Elon lights the fuse.
Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...
Crypto 101 Media | Sponsoredtc pixel